REPROCELL, IBM and STFC harness the power of AI in drug discovery and precision medicine
31 August 2022
New collaboration at Hartree National Centre for Digital Innovation combines REPROCELL’s tests of drug efficacy in human living tissues with IBM expertise in artificial intelligence and machine learning. Glasgow, UK and Daresbury, UK: REPRO...
Preclinical studies by REPROCELL give COPD drug a final boost before clinical trials
17 August 2022
Glasgow UK - 17 August 2022: A drug being developed for the treatment of severe asthma and COPD has passed an important milestone. Scientists at REPROCELL compared the effects of the compound, RCD405, with drugs that are currently used to t...
Life science after lockdown: SPS returns for 2022
15 August 2022
Next month, the Safety Pharmacology Society (SPS) will be hosting its first in-person meeting since 2019. Now in its 22nd year, this dynamic forum is known for its global networking opportunities and events promoting the best practices in s...
Bioserve India granted NABL accreditation in the field of Genomics Testing
09 August 2022
Hyderabad, India - 9 August 2022: We are pleased to announce that Bioserve Biotechnologies India Pvt Ltd, a subsidiary of REPROCELL Inc, has received NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation...
Completion of Clinical Phase II Trials of Stemchymal in Japan
16 May 2022
Yokohama Japan, 16 May 2022: We are pleased to announce that the Clinical Phase II Trial of Stemchymal, a regenerative medicine product derived from somatic stem cells, has been completed in Japan. Previously, on 24 May 2021, we announced t...
REPROCELL co-author paper with IBM showcasing a novel ML driven precision medicine strategy for drug development
08 March 2022
Glasgow UK - 25 February 2022: REPROCELL, in collaboration with researchers at IBM and the Precision Medicine Scotland Innovation Centre, have co-authored a publication aiming to improve precision medicine strategies. The paper, titled "Com...
REPROCELL spotlights the power of smarter biospecimens in new global publication
21 January 2022
Glasgow UK - 21 January 2022: REPROCELL has published an article highlighting the power of human biospecimens in the latest issue of European Biopharmaceutical Review (EBR). The piece, titled Dynamizing Biomarker R&D with Smarter Biospecime...
Hoth Therapeutics Extends Partnership Agreement with REPROCELL
25 October 2021
GLASGOW, October 25, 2021: Hoth Therapeutics, Inc. (NASDAQ: HOTH) has extended its partnership agreement with REPROCELL to assess the effect of the HT-003 therapeutic platform in inflammatory bowel disease (IBD). Fresh explants of ulcerativ...
Bioserve India to sponsor webinar hosted by the Society of Fetal Medicine
15 September 2021
Hyderabad India – 15 September 2021: Bioserve Biotechnologies India Pvt. Ltd. (a 100% owned subsidiary of REPROCELL Inc) will sponsor a webinar series hosted by the Society of Fetal Medicine in September. The title of the webinar is “Geneti...
REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service
02 September 2021
Yokohama Japan, 02 September 2021: REPROCELL have signed a Strategic Collaboration Agreement with TEXCELL JAPAN, a TEXCELL Group Company, for GMP iPSC - Master Cell Banks (MCB) Manufacturing. The TEXCELL Group (hereinafter “TEXCELL”) is a c...